EUVIMEDEUVIMED entdecken
Crossref

Real‐World Assessment of rVIII‐SingleChain for Prophylactic Treatment in People With Severe Hemophilia A in High‐Resource Settings

Te-Fu Weng, Shu-Huey Chen, Yeu-Chin Chen

Haemophilia · 2026-11 · 32 (6) · 1421-1428

DOI: 10.1111/hae.70349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 05.07.2026. Verfasst von Te-Fu Weng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Health Resources. Die Arbeit nennt 29 Literaturangaben. Gefördert von: CSL Behring.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction rVIII‐SingleChain has been approved and reimbursed in Taiwan since September 2020 as prophylaxis for severe hemophilia A.

Aim

This study compared real‐world outcomes of prophylactic treatment with rVIII‐SingleChain versus other long‐acting FVIII products in people with severe hemophilia A (PwSHA) in Taiwan.

Methods

A retrospective de‐identified patient chart‐review‐based study was conducted in three hemophilia treatment centers in Taiwan (September 2019‐August 2021). Data of PwSHA who used rVIII‐SingleChain or other long‐acting FVIII products for prophylaxis (for ≥12 weeks following 1 September 2020) were included. Current treatment regimen, factor consumption, and bleeding events (annualized bleeding rate [ABR], annualized joint bleeding rate [AjBR], annualized spontaneous bleeding rate [AsBR]) data were collected from medical records.

Results

Overall, 39 patients were enrolled (rVIII‐SingleChain: n = 14; other long‐acting FVIII products: n = 25). Median (IQR) factor VIII consumption (IU/kg/week) was: 97.7 (92.3–103.2) for rVIII‐SingleChain and 81.4 (71.0–90.3) for other long‐acting FVIII products; 11/14 patients (78.6%) and 23/25 patients (92.0%), respectively, were dosed ≤2 times/week. Median (IQR) bleeding rates of rVIII‐SingleChain versus other long‐acting FVIII products were: ABR, 0.0 (0.0–9.8) vs 2.0 (0.0–5.0); AsBR, 0.0 (0.0–3.3) vs 1.0 (0.0–4.0); and AjBR, 0.0 (0.0–7.6) vs 0.0 (0.0–5.0). Half‐life (hr) was comparable between O and non‐O blood type patients for rVIII‐SingleChain (mean ± SD: 15.3 ± 6.3 vs 17.8 ± 2.2; p = 0.1243) and rurioctocog alfa pegol (15.3 ± NA vs 17.6 ± 2.8; p = 0.3711); but significantly higher in non‐O than O blood type for efmoroctocog alfa (20.6 ± 3.6 vs 14.6 ± 3.9; p = 0.0292). Conclusion rVIII‐SingleChain prophylactic treatment demonstrated effective bleeding control in PwSHA in Taiwan, with low dosing frequency (≤2 times/week) in most PwSHA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIHealth ResourcesHumansMaleRetrospective StudiesAdultHemorrhageAdolescentTaiwanYoung AdultTreatment OutcomeChild

Stichwörter der Autor:innen

bleeding ratehalf‐lifehemophilia Along‐acting FVIII productprophylaxisrVIII‐SingleChain

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Shuang-Ho Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan.
  • Hemophilia Care & Research Center, Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.

Förderung

  • CSL Behring

Zitieren

APA

Weng, T. F., Chen, S. H., & Chen, Y. C. (2026). Real‐World Assessment of rVIII‐SingleChain for Prophylactic Treatment in People With Severe Hemophilia A in High‐Resource Settings. Haemophilia, 32(6), 1421-1428. https://doi.org/10.1111/hae.70349

Vancouver

Weng TF, Chen SH, Chen YC. Real‐World Assessment of rVIII‐SingleChain for Prophylactic Treatment in People With Severe Hemophilia A in High‐Resource Settings. Haemophilia. 2026;32(6):1421-1428. doi:10.1111/hae.70349

BibTeX
@article{Weng2026,
  author = {Weng, Te-Fu and Chen, Shu-Huey and Chen, Yeu-Chin},
  title = {Real‐World Assessment of rVIII‐SingleChain for Prophylactic Treatment in People With Severe Hemophilia A in High‐Resource Settings},
  journal = {Haemophilia},
  year = {2026},
  volume = {32},
  number = {6},
  pages = {1421--1428},
  doi = {10.1111/hae.70349}
}
Kostenlos starten →